Chimerix, Inc. (CMRX) CEO Mike Sherman on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
Chimerix Reports First Quarter 2022 Financial Results and Provides Operational UpdateGlobeNewsWire • 05/16/22
Chimerix stock surges after deal to sell smallpox treatment Tembexa for up to $337.5 million, plus royaltiesMarket Watch • 05/16/22
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus RoyaltiesGlobeNewsWire • 05/16/22
Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational UpdateGlobeNewsWire • 03/01/22
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral ResearchGlobeNewsWire • 02/24/22
Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical StudiesBenzinga • 02/24/22
Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022GlobeNewsWire • 02/22/22
Will Chimerix (CMRX) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/17/22